Want to see COLL full AI Analyst Report?
COLL Stock Chart & Stats
$35.20
-$0.39(-1.10%)
At close: 4:00 PM EDT
$35.20
-$0.39(-1.10%)
Day’s Range― - ―
52-Week Range$25.47 - $50.79
Previous Close$35.2
Volume254.18K
Average Volume (3M)420.68K
Market Cap
$882.58M
Enterprise Value$2.24K
Total Cash (Recent Filing)$129.47M
Total Debt (Recent Filing)$857.79M
Price to Earnings (P/E)17.9
Beta0.38
Next Earnings
Nov 05, 2026EPS Estimate
1.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.53
Shares Outstanding32,555,614
10 Day Avg. Volume364,031
30 Day Avg. Volume420,684
Financial Highlights & Ratios
PEG Ratio-3.13
Price to Book (P/B)4.87
Price to Sales (P/S)1.88
P/FCF Ratio4.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$49.25Price Target Upside39.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)7.47
Revenue Forecast (FY)$869.86M
Bulls Say, Bears Say
Bulls Say
ADHD Franchise GrowthJornay PM revenue rose 41% year over year, prescriptions grew 13.1%, and branded long-acting methylphenidate share reached 29.2%. This sustained adoption supports durable ADHD franchise expansion and reduces reliance on mature pain products.
Azstarys Portfolio ExpansionAzstarys adds a complementary ADHD product with IP protection through 2037. Early sales of $12.9 million and raised guidance indicate commercialization traction, while the expanded sales force can support multi-year portfolio growth.
Strong Cash GenerationOperating cash flow was about $330 million in 2025 and TTM, while TTM free cash flow was about $328 million. Strong conversion indicates earnings are cash-backed and provides capacity for debt service, reinvestment, and disciplined portfolio development.
Bears Say
Elevated Balance-Sheet LeverageTTM debt of about $1.10 billion compares with $312 million of equity, or roughly 2.6x debt-to-equity; net debt to adjusted EBITDA was about 2.1x after acquisition. This leverage can constrain flexibility and amplify earnings or refinancing risk.
Pain Portfolio ErosionNUCYNTA revenue fell 24% year over year and Xtampza ER fell 14%, reflecting authorized-generic pricing and broader branded long-acting opioid pressure. Persistent erosion in these brands could offset ADHD growth and weaken portfolio diversification.
Belbuca Loss-of-Exclusivity RiskBelbuca faces potential generic entry in January 2027 under settlement provisions. Loss of exclusivity could reduce pricing power and prescription revenue, weakening a currently growing pain product and increasing dependence on the ADHD franchise.
Collegium Pharmaceutical News
COLL FAQ
What was Collegium Pharmaceutical Inc.’s price range in the past 12 months?
Collegium Pharmaceutical Inc. lowest stock price was $25.47 and its highest was $50.79 in the past 12 months.
What is Collegium Pharmaceutical Inc.’s market cap?
Collegium Pharmaceutical Inc.’s market cap is $882.58M.
When is Collegium Pharmaceutical Inc.’s upcoming earnings report date?
Collegium Pharmaceutical Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 71 days.
How were Collegium Pharmaceutical Inc.’s earnings last quarter?
Collegium Pharmaceutical Inc. released its earnings results on Aug 06, 2026. The company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.719 by $0.201.
Is Collegium Pharmaceutical Inc. overvalued?
According to Wall Street analysts Collegium Pharmaceutical Inc.’s price is currently Undervalued.
Does Collegium Pharmaceutical Inc. pay dividends?
Collegium Pharmaceutical Inc. does not currently pay dividends.
What is Collegium Pharmaceutical Inc.’s EPS estimate?
Collegium Pharmaceutical Inc.’s EPS estimate is 1.86.
How many shares outstanding does Collegium Pharmaceutical Inc. have?
Collegium Pharmaceutical Inc. has 32,555,614 shares outstanding.
What happened to Collegium Pharmaceutical Inc.’s price movement after its last earnings report?
Collegium Pharmaceutical Inc. reported an EPS of $1.92 in its last earnings report, beating expectations of $1.719. Following the earnings report the stock price went down -18.551%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical Inc.?
Currently, no hedge funds are holding shares in COLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Collegium Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.25 (39.91% Upside)
$49.25 (39.91% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 797.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
34.10%
Trailing 12-Months
Company Description
Collegium Pharmaceutical Inc.
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
COLL Company Deck
COLL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong, accelerating growth in the ADHD franchise—Jornay PM momentum, the strategic Azstarys acquisition with early revenue and raised guidance, Belbuca growth and incremental formulary wins, and an 8% increase in adjusted EBITDA. Offsetting these positives were meaningful declines in the NUCYNTA franchise driven by authorized generic pricing, a decline in Xtampza ER, a GAAP net loss driven by acquisition-related costs, substantial cash deployed to acquire Azstarys and a modest leverage increase, and potential LOE risk for Belbuca. Overall, management presented a constructive outlook focused on ADHD-led growth and disciplined capital deployment while acknowledging near-term pain portfolio pressures and one-time acquisition impacts.View all COLL earnings summariesCOLL Stock 12 Month Forecast
Average Price Target
$49.25
▲(39.91% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Indivior
―
Amneal Pharmaceuticals
―
Aquestive Therapeutics
―
Ownership Overview
3.30% Insiders
30.54% Mutual Funds
26.92% Other Institutional Investors
6.41% Public Companies and
Individual Investors